Stallergenes

external image logo_stallergenes_fr.gif





General Information

Company Name
Stallergenes
Year founded
1962
Headquarters
Antony, France
Number of Locations
44
Global locations
ALGERIA, AUSTRALIA, AUSTRIA
BAHRAIN, BELGIUM, BULGARIA
CANADA, CZECH REPUBLIC
GERMANY, GREECE
HONG KONG, HUNGARY
ITALY
JORDAN
KOREA, KUWAIT
LATVIA, LEBANON, LITHUANIA
MALAYSIA, MAROCCO
NETHERLANDS, NEW ZEALAND
POLAND, PORTUGAL
QATAR
ROMANIA, RUSSIA
SAUDI ARABIA, SINGAPORE, SLOVAK REPUBLIC, SLOVENIA,
SOUTH AFRICA, SPAIN, SWITZERLAND, SYRIA
TUNISIA, TURKEY
UNITED ARAB EMIRATES, UNITED KINGDOM
VIETNAM
Key People
Albert SAPORTA, Chairman and CEO.
Louis CHAMPION, Francisco MARTINEZ
Revenue
193 000 000 €uros
Operating Income
32 200 000 €uros
Net Income
22 200 000 €uros
Employees
850
website
http://www.stallergenes.com
external image principale.jpg
Stallergenes is an European biopharmaceutical laboratory which dedicates itself to the treatments of desensitization for the prevention and the treatment of the allergic respiratory diseases such as the rhinoconjonctivite and the allergic asthma. Pioneer and leader of the treatments of desensitization sublinguale, Stallergenes dedicates 20 % in raw data of its revenue to the research and development and is engaged in the development of a new therapeutic class: sublinguaux tablets of desensitization.
In 2007, the company realized 147 million euro of revenue and more than 500 000 patients were treated with products of desensitization Stallergenes. Stallergenes represents 13 clinical trials, 5,000 patients included in the stalair® programme

History


1962
- Creation of Stallergenes by the Institut Mérieux, a world leader in vaccines
1986
- Stallergenes develops and supplies one of the first anti-allergies vaccines to be administered orally.
1988
- First NPP automated production chain implemented by Stallergenes
1989
- Merger of Stallergenes with the Allergen Division - Institut Pasteur
1992
- Expansion of Stallergenes in Greece, Spain, Portugal and Turkey
1993
- Acquisition of Stallergenes by Wendel Investissement
1994
- Launch of Staloral® (allergen immunotherapy by sublingual delivery)
1997
- Establishment in Antony (Paris area)
1998
- Introduction of Stallergenes to the Second Market of the Paris Stock Exchange
1999
- With the purchase of DHS, the allergy division of Bayer Pharma, the Stallergenes-DHS Group becomes the world's number 2 company in its sector
- Awarded international ISO 9001 certification
2002
- Launch of Staloral 300® (desensitisation therapy via sublingual drops) in Europe
2003
- Initiation of the first clinical study comparing the efficacy of a recombinant allergen tablet to a current product.
2004
- Launch of a clinical study on the Grasses sublingual tablet, which represents a new therapeutic class and a significant advance for patients
2005
- Acquisition of IPI's desensitization activity in Spain and Portugal
- Success of the clinical study on the Grasses tablet
2006
- Positive results from the first Proof of concept clinical study comparing the efficacy of a recombinant allergen (Bet v 1) with the current product based on a natural birch pollen extract.
- Results of the Phase I safety study of the Mites desensitisation tablet.
2007
- Development of a first product candidate as part of the Enhanced Allergens program with a view to pharmaceutical and preclinical development.
- Commitment to the development and production of recombinant birch pollen and dust mites allergens (Partnerships with CMC and Protein'Expert)
- Positive results for the phase III clinical study of grass pollen induced rhino-conjuctivitis in children (sublingual desensitisation tablet)
- Start of two clinical studies : a phase II/III for mite induced allergic rhinitis in adults (mites tablet) in Europe ; a phase III for mite induced allergic asthma in adults (sublingual desensitisation drops treatment)
2008
- Achievement of the market authorization of the sublingual desensitisation tablet Oralair® in Germany,
- Obtaining of market authorization in Gernany for Oralair® ,sublingual grass pollen desensitization tablet, for adult use.
- Extremely positive clinical results in a pharmacodynamic study carried out in an allergen challenge chamber with Oralair® (V056.07).
- Partnership with Catalent and The Medical House for the European marketing of an adrenalin auto-injector (Adreflex®)
- Launch of a phase IIb/III trial in Europe for the treatment of allergic rhinoconjunctivitis induced by birch pollen in adults, with a tablet containing the major recombinant allergen for this pollen, r Bet v 1
- Launch of a phase III clinica trial in the United States with Oralair® for the treatment of allergic rhinoconjunctivitis induced by grass pollen in adults (V061.08).
- Launch of a new phase III in Europe with Oralair® for grass-induced rhinoconjunctivitis in adults and adolescents in an optimised protocol (V060.08)
2009
- Obtaining of a paediatric marketing authorization in Germany for Oralair®.
-Positive results for the phase IIb/III clinical trial (V057-07) for house dust mite induced allergic rhinitis in adults.


Products



The company developes a wide and complete range of diagnostic and therapeutic products. About the treatement two forms of products are currently available: sublingual drops developed by the Stallergenes' research team and the subcutaneous injections.

  • Staloral® is a sublinguale solution of Allergenic extracts Prepared Specially for an Individual. Staloral® is indicated in the rhino-conjunctivitis allergic to pollens, to acarids, to molds and to phanères (hairs of animals). Staloral® is available in most of the European countries.



  • Alustal® mite extracts, ALUSTAL pollen extracts and ALUSTAL animal extracts (ALUSTAL allergen extracts) contain a single allergen extract or a combination of allergen extracts within the mite, animal or pollen group of allergens. It is an allergen extracts belong to a group of medicines called Anti-allergy preparations which are indicated for patients with allergic reactions particularly presenting as seasonal rhinitis, conjunctivitis, rhino-conjunctivitis with or without associated asthma.



  • Oralair® Grasses is a tablet of desensitization fast-dissolution sublinguale indicated in the rhino-conjunctivitis allergic to pollens of grasses for patients presenting symptoms moderated in severe dissatisfied and or insufficiently controlled by the symptomatic treatments. It contains a mixture of five standardized allergens of grasses, external image 03_arz08_10.jpgreproducing the natural exposure of the patients: rye grass (Lolium perenne), pâturin (Poa pratensis), phléole (Phleum pratense), dactyl (Dactylis glomerata) and flouve (Anthoxanthum odoratum). Oralair®
Grasses in the other short-term European countries, in both indications. received, in June, 2008, an authorization of launch on the market in the grown-up indication in Germany and waits for an extension of pediatric indication by the end of the year. Stallergenes will launch then a procedure of mutual recognition to market Oralair




Financial Information


The 2009 sales growth dynamics (up 13%, 12% organic) as well as strict control on operating expenses (63.2% of sales vs 66.0% in 2008, before R&D) enabled the Group to both absorb research efforts
(up 26%, representing 24% - gross - of sales) and further improve profit margins:
  • operating profit totalled EUR 32.2 million, that underlined an operating profit margin of 16.7% (16.5% in 2008).
  • Net profit grew for the ninth consecutive year by 17% to EUR 22.2 million, generating an 11.5% net profit margin (11.1% in 2008).


external image RTEmagicC_tableau_UK_2009.JPG.jpg


  1. bioinformatics
  2. biopharmaceutical
  3. company
  4. genetic tests
  5. monoclonal antibodies
  6. nanobiotechnology
  7. penicillin; antibiotics
  8. pharmaceutical
  9. poland
  10. portugal
  11. product
  12. technology
  13. tool
  14. vaccine


Tony Mickael Dinis (n°aluno: 68884)